Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.39 |
| ▸ | PLG | P00747 | 5/20 | 0.38 |
| ▸ | KLK1 | P06870 | 5/20 | 0.38 |
| ▸ | KLK6 | Q92876 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6292878 | 0.99 | SERPINE1 (0.43) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL8431843 | 0.80 | CA12 (0.66) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL7582391 | 0.80 | NR1H2 (0.41) | SERPINE1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL6289084 | 0.79 | CA12 (0.64) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL22767197 | 0.78 | LOXL2 (0.58) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1165530 | 0.76 | GAA (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6292886 | 0.75 | EGFR (0.38) | TDP1 | |
| Hydrochloric Acid SCHEMBL2894768 | 0.75 | GAA (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7896621 | 0.73 | CA12 (0.60) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL7647483 | 0.73 | ERCC1 (0.38) | GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6870065-B2 | Bifunctional boronic compound complexing reagents and complexes | CAMBREX BIO SCIENCE ROCKLAND, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | AHLEM CLARENCE N (US) | 2003-06-05 | — | — | US | disclosed |
| US-6414122-B1 | BIOCHEMICAL CONJUGATION TO PROTEINS, PEPTIDES, HORMONES, POLYSACCHARIDES, NUCLEIC ACIDS, LIPOSOMES, RADIONUCLIDES, HAPTENS, AND TOXINS | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-6156884-A | Bifunctional boronic compound complexing reagents and complexes | PROLINX, INC. (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105280-A1 | Bifunctional boronic compound complexing reagents and complexes | CHN2, CFH, COG2 | SERPINE1 4299/4885CA12 89/4885CA1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.